MedPath

Virtual Reality on Pain, Stress, and Affect in the Infusion Clinic

Not Applicable
Completed
Conditions
Chemotherapy
Cancer
Interventions
Behavioral: Questionnaires
Behavioral: Virtual reality therapy
Procedure: Measure heart rate
Behavioral: Cyber sickness measurement
Registration Number
NCT05135260
Lead Sponsor
Cody Stansel
Brief Summary

This study will investigate the ability of virtual reality to function as a novel distraction intervention and improve the experience of patients who are receiving chemotherapy in the infusion clinic.

Detailed Description

Objectives:

Primary Objective:

- To deploy and evaluate virtual reality as an intervention for stress, pain, and negative affect

Secondary Objective:

- To evaluate cyber sickness and patient satisfaction related to the virtual reality treatment

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
99
Inclusion Criteria
  • At or above the age of 18
  • English Speaking
  • Diagnosed with cancer
  • No previous history of seizures, losses of awareness, or other symptoms linked to an epileptic condition
  • Not sensitive to motion sickness
  • Not currently experiencing any contagious conditions, infections, or diseases (particularly of the eyes, skin, or scalp)
  • Does not use a device to regulate heart rate or rhythm (such as a pacemaker)
  • Not taking antiarrhythmic medications
  • Not actively receiving radiopharmaceutical therapy

Exclusion:

  • To ensure that there is sufficient time to complete the virtual reality treatment, patients who are scheduled for visits for periods of less than one hour will not be included in this study. Additionally, patients must consent to participating in the study on the day of the experience.
  • Patients who are asleep prior to consenting will not be asked to participate in the study
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Virtual Reality TherapyMeasure heart rateParticipants will watch videos for 11 minutes that will allow them to view nature, dinosaurs, animals, and human interactions in three dimension.
Control GroupQuestionnairesThis group will not watch videos, but will continue with their normal routine as if nothing has changed.
Virtual Reality TherapyCyber sickness measurementParticipants will watch videos for 11 minutes that will allow them to view nature, dinosaurs, animals, and human interactions in three dimension.
Control GroupMeasure heart rateThis group will not watch videos, but will continue with their normal routine as if nothing has changed.
Virtual Reality TherapyVirtual reality therapyParticipants will watch videos for 11 minutes that will allow them to view nature, dinosaurs, animals, and human interactions in three dimension.
Virtual Reality TherapyQuestionnairesParticipants will watch videos for 11 minutes that will allow them to view nature, dinosaurs, animals, and human interactions in three dimension.
Primary Outcome Measures
NameTimeMethod
Positive or negative effect of Virtual Reality therapy on improving the experience of participants receiving chemotherapyApproximately 12 months

Measured by the Positive and Negative Affect Scale (0=minimum to 5=maximum). Consisting of a number of words that describe different feelings and emotions. Patients are instructed to indicate to what extent they currently feel each of the feelings or emotions. Afterwards, patient responses are scored to produce a numerical positive affect score and a negative affect score.

Measure the affect of Virtual Reality Therapy on improving stressApproximately 12 months

Measured by stress level using the stress numerical rating

Measure the affect of Virtual Reality Therapy on improving painApproximately 12 months

Measured by pain level using the pain numerical score (scale 0 (none) to 10 (worst)

Secondary Outcome Measures
NameTimeMethod
Rate of cyber sickness (Virtual Reality Therapy Arm Only)Approximately 12 months

Measured with the Fast MS Scale (FMS), a verbal rating scale ranging from zero (no sickness at all) to 20 (frank sickness).

Trial Locations

Locations (1)

Vanderbilt-Ingram Cancer Center

🇺🇸

Nashville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath